Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Completed 5No longer available 1

Sponsor Class

OTHER 7INDUSTRY 6

Study Type

Interventional 5Expanded_access 1

Sponsor

Cancer Type

CNS 3Dermatologic 2Genitourinary 1

Conditions

Glioblastoma 3Nervous System Neoplasms 2Nervous System Diseases 2Neoplasms 2Melanoma 2Glioma 2Central Nervous System Neoplasms 2Central Nervous System Diseases 2Brain Neoplasms 2Brain Diseases 2Astrocytoma 2Carcinoma, Renal Cell 1

Interventions

pembrolizumab 1033Carboplatin 971Paclitaxel 942Gemcitabine 799Cisplatin 757Docetaxel 698Bevacizumab 637Nivolumab 520Pemetrexed 507Capecitabine 475Cyclophosphamide 473Fluorouracil 425Dexamethasone 410Rituximab 391Oxaliplatin 352Injections 347Trastuzumab 314atezolizumab 312Cetuximab 291Leucovorin 290Irinotecan 271130-nm albumin-bound paclitaxel 257Prednisone 251Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 219durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
INDUSTRY × Cancer Vaccines × Clear all
NCT05936216 2024-10-01

TVI-Brain-1 in Expanded Access Patient

TVAX Biomedical

No longer available
CNS

Glioblastoma

NCT01290692 2023-07-03

Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma

TVAX Biomedical

Phase 2 Completed
14 enrolled 11 charts
CNS

Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma, Neoplasms, Nervous System Diseases, Nervous System Neoplasms, Central Nervous System Neoplasms

NCT01081223 2023-06-01

Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma

TVAX Biomedical

Phase 1/2 Completed
12 enrolled 11 charts
CNS

Astrocytoma, Brain Diseases, Brain Neoplasms, Central Nervous System Diseases, Glioblastoma, Glioma, Neoplasms, Nervous System Diseases, Nervous System Neoplasms, Central Nervous System Neoplasms

NCT01684241 2020-01-18

MERIT

BioNTech SE

Phase 1 Completed
29 enrolled
Dermatologic

Melanoma

NCT02035956 2020-01-18

IVAC MUTANOME Phase I Clinical Trial

BioNTech SE

Phase 1 Completed
15 enrolled
Dermatologic

Melanoma

NCT01525017 2015-10-12

A Clinical Study to Evaluate Safety and Immunologic Response of COMBIG-DC, in Patients With Metastatic Kidney Cancer

Mendus

Phase 1 Completed
12 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡